Previous Close | 53.00 |
Open | 53.50 |
Bid | 53.50 x N/A |
Ask | 55.50 x N/A |
Day's Range | 53.50 - 53.50 |
52 Week Range | 32.00 - 61.00 |
Volume | |
Avg. Volume | 10 |
Market Cap | 39.229B |
Beta (5Y Monthly) | 0.64 |
PE Ratio (TTM) | 58.79 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.41 (0.77%) |
Ex-Dividend Date | May 15, 2024 |
1y Target Est | N/A |
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.